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Abstract  
A 61-year old woman with a previous history of pernicious anemia presented with progressive 
muscle weakness and dysarthria. She was diagnosed with hypokalemic paralysis (serum 
potassium 1.4 mEq/L) due to distal renal tubular acidosis (dRTA). After excluding several 
possible causes, dRTA was considered autoimmune. However, the patient did not meet the 
criteria for any of the autoimmune disorders classically associated with dRTA. She did have 
very high antibody titers against parietal cells, intrinsic factor, and thyroid peroxidase (but 
with normal thyroid function). The patient consented to a kidney biopsy. Immunofluorescence 
studies revealed the absence of the acid-base transporters anion exchanger type 1 (AE1) and 
pendrin. Indirect immunofluorescence studies demonstrated (1) diminished abundance of  
AE1 and pendrin expressing intercalated cells in her kidney, and positive staining by her 
serum of (2) normal human intercalated cells and (3) parietal cells expressing the H
+
/K
+
-
ATPase pump in normal human gastric mucosa. The dTRA is likely caused by circulating 
autoantibodies against intercalated cells (with possible crossreactivity against structures 
containing the gastric H
+
/K
+
-ATPase pump).  
This case demonstrates that in patients with dRTA without a classical autoimmune disorder, 
autoimmunity may still be the underlying cause. The mechanisms why autoantibodies are 
developed and how highly specific autoantibodies against intercalated cells can cause dRTA 
remains to be uncovered. 
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Introduction 
Distal renal tubular acidosis (dRTA, also called type I RTA) is caused by an inability of the 
kidney collecting duct to acidify urine (1). The metabolic acidosis in dRTA is characterized 
by a normal anion gap, urinary pH > 5.3, and low ammonium excretion. dRTA is usually 
caused by a proton secretion defect in the intercalated cells. This proton secretion defect 
explains why dRTA is usually accompanied by hypokalemia, because it indirectly causes 
renal potassium losses and cellular shifts of potassium. dRTA may be inherited or acquired by 
drugs, hypercalciuria, or an underlying autoimmune disorder (2). It has been reported in 
various autoimmune disorders including Sjögren’s syndrome, primary biliary cirrhosis, 
autoimmune hepatitis, systemic lupus erythematosus, and rheumatoid arthritis (2). How these 
autoimmune disorders cause dRTA is not well known. dRTA is a relatively common 
complication of Sjögren’s syndrome, and studies have suggested the presence of 
autoantibodies against acid-base transporters (3-5). Here, we report a case of dRTA associated 
with circulating antibodies against intercalated cells. Surprisingly, the patient did not have one 
of the systemic autoimmune disorders associated with dRTA, but did have multiorgan 
autoimmunity involving the kidney, stomach and thyroid glands. 
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Case report 
A 61-year old woman presented with progressive muscle weakness and dysarthria since one 
week. Her dietary habits were unremarkable and she did not have diarrhea. She used no other 
medication than folic acid (5 mg/day) and vitamin B12 injections because of pernicious 
anemia (her only medical history). She did not use H2-receptor antagonists or proton pump 
inhibitors. Besides paralysis (muscle strength 2/5), physical examination was normal, 
including examination of the thyroid. Laboratory tests at admission revealed severe 
hypokalemia (serum potassium 1.4 mEq/L) and non-anion gap metabolic acidosis (serum pH 
7.14, bicarbonate 9 mEq/l). Hypokalemia was due to renal potassium losses (urine potassium 
20 mEq/l, fractional potassium excretion 21%). The metabolic acidosis was characterized by 
an inappropriately high urine pH of 7.1 and a positive urine anion gap (+21 mEq/l), 
suggesting renal tubular acidosis (RTA). Other laboratory tests were normal, including 
thyroid and kidney function. She had normal sized kidneys without nephrocalcinosis. The 
patient was hospitalized for several weeks, initially at the intensive care unit for intravenous 
potassium and bicarbonate supplementation under telemetry, and is currently still treated with 
oral sodium bicarbonate (1500 mg daily) and potassium citrate (1800 mg daily) maintaining a 
normal serum potassium (4.1 mEq/L) and bicarbonate (25 mEq/L). She is currently followed-
up as outpatient for electrolyte and acid-base balance, and gastric and thyroid function.   
 
After the acute phase, additional tests were performed to investigate the type and cause of 
RTA. An acidification test using fludrocortisone and furosemide was performed during which 
she failed to reach a urine pH < 5.3 (lowest urine pH 5.5) (6). In addition, renal ammonium 
excretion was assessed by calculating the urine osmolal gap and found to be very low in view 
of the existing acidosis (11 mEq/l). These findings confirmed dRTA, although a fractional 
bicarbonate excretion test was not performed to formally exclude a proximal RTA. The 
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diagnosis was further supported by the absence of other markers of proximal tubular 
dysfunction (no hypouricemia, hypophosphatemia, proteinuria or glucosuria), and the absence 
of paraprotein and urinary light chains. Although no previous measurements of serum 
potassium or bicarbonate were available, a hereditary form of dRTA seemed unlikely 
(negative family history, late age of presentation). Repeated history and physical examination 
did not provide clues for a systemic autoimmune disorder. There was no hypercalciuria. 
Antinuclear antibodies, anti-neutrophil cytoplasmic antibodies and rheumatoid factor tested 
negative, as did antibodies against SS-A, SS-B, and tissue transglutaminase. Antibodies 
against parietal cells, intrinsic factor (titers not available), and thyroid peroxidase (titer >1300 
IU/mL, normal range < 60 IU/mL), however, were strongly positive. 
 
With informed consent of the patient, a kidney biopsy was performed. Light microscopy 
showed normal glomeruli and an atrophic aspect of some of the proximal tubuli without any 
other histological changes (data not shown). Subsequently, we performed indirect 
immunofluoresence on the patient’s kidney tissue and with the patient’s serum on normal 
human kidney and stomach tissue. In the indirect immunofluorescence studies we tested 
aquaporin-2 (AQP2) as marker of principal cells and three acid-base transporters in 
intercalated cells, including the a4 and B1 subunits of the proton pump (H
+
-ATPase), the 
anion exchanger 1 (AE1, a marker for acid-secretory type A intercalated cells), and pendrin (a 
marker for bicarbonate-secretory type B intercalated cells). Remarkably, staining for AE1 and 
pendrin was absent in the patient’s kidney (Figure 1). Although residual staining for the a4 
and B1 subunits was present, these co-localized in the same cells with AQP2 (Figure 1).  
 
The incubation with the patient’s serum on normal human kidney caused strong staining 
exclusively in both types of intercalated cells, whereas this was not present with control sera 
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from 5 persons (male and female, age between 30-60 years) (Figure 2). To confirm that the 
staining occurred in intercalated cells, we performed double labelling with AE1 (green) and 
AQP2 (white, Figure 2). These studies showed that the patient’s serum stained type A 
intercalated cells because of co-localization with AE1. Because the patient’s serum also 
stained cells that were negative for AE1 and AQP2, we believe this additional staining 
occurred in type B intercalated cells. In gastric tissue, staining for the α-subunit of H+/K+-
ATPase, a marker of acid-secretory parietal cells in the gastric mucosa, revealed a strong 
overlay with the signal from the patient’s serum (green) and the α-subunit of the H+/K+-
ATPase (red) (Figure 2). The staining appeared to have partial but substantial overlap, 
suggesting that the pump itself or associated proteins are part of the antigen. With control 
serum there was no staining for cells expressing the α-subunit of the H+/K+-ATPase (Figure 
2). 
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Discussion 
We report an unusual case of dRTA, which was clearly of autoimmune origin, but could not 
be linked to any systemic autoimmune disorder known to be associated with dRTA. By 
performing indirect immunofluorescence studies we demonstrate (1) diminished abundance of  
AE1 and pendrin expressing intercalated cells in the kidney of the patient, and positive 
staining by the patient’s serum of (2) normal human intercalated cells and (3) parietal cells 
expressing the H
+
/K
+
-ATPase pump in normal human gastric mucosa. We conclude that 
dTRA is likely caused by circulating autoantibodies against intercalated cells with possible 
crossreactivity against structures containing the gastric H
+
/K
+
-ATPase pump. The co-
localization of H
+
-ATPase with AQP2 may suggest that intercalated cells have either 
completely disappeared and that principal cells express some markers of intercalated cells or 
that the differentiation process is affected by autoantibodies and that cells coexpressing H
+
-
ATPases and AQP2 represent an intermediate cell type as has been reported in mice lacking 
the transcription factor Foxi1 which is required for normal intercalated cell differentiation (7).  
It is unclear if one common epitope is present in kidney, stomach, and possibly thyroid, or 
whether multiple autoantibodies target different epitopes in these three tissues. The B1 
subunit of H
+
-ATPase is not expressed in stomach or thyroid glands whereas the ubiquitious 
B2 subunit is present in every tissue and cell type. Also, pendrin and AE1 are absent from 
stomach. In addition, cross-reactivity of the patient’s serum with red blood cells would be 
expected in the case of AE1 reacting autoantibodies (4). Moreover, patients with mutations in 
AE1 or H
+
-ATPase subunits are not known to have thyroid or gastric disorders (8). 
Autoantibodies against pendrin have been reported in patients with auto-immune thyroiditis 
and hypothyroidism (9). Patients with mutations in pendrin present with deafness that can be 
accompanied by goiter and hypothyroidism; electrolyte and acid-base disorders have only 
been reported in these patients in the context of thiazide use or inter-current illness (9-11). 
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Also, the pathogenesis of dRTA is difficult to reconcile with dysfunctional pendrin, because 
this transporter is involved in renal bicarbonate secretion and sodium chloride reabsorption. 
Another candidate protein would be SLC26A7, although we did not analyze this transporter in 
our immunolabeling studies. SLC26A7 is expressed in intercalated cells and stomach and 
mice lacking SLC26A7 suffer from RTA and reduced gastric acid secretion (12). Of interest, 
the constellation of autoantibodies against parietal cells, intrinsic factor, and thyroid 
peroxidase and the occurrence of dRTA has been reported previously (13). In this series of 
113 patients, a complement fixing autoantibody was identified that reacted with the renal 
collecting duct. 
 
In conclusion, this unusual case demonstrates that in patients with dRTA, autoimmune 
disorders must be considered that do not fit the classic disorders associated with dRTA. The 
diagnosis can be made by the combination of excluding these classic syndromes and the 
demonstration of autoantibodies against affected organs. The exact mechanisms why 
autoantibodies are developed and how highly specific autoantibodies against intercalated cells 
can cause dRTA remains to be uncovered. 
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Figure 1: Loss of intercalated cells expressing AE1 and pendrin in the patient’s kidney 
(A) Healthy human kidney was stained for AE1 (green) and the B1 H
+
-ATPase subunit, and 
cell nuclei (blue). (B) The patient’s kidney shows no staining for AE1 in collecting ducts (*) 
but in red blood cells (arrow). (C) Healthy human kidney stained for pendrin (green), AQP2 
(white), the a4 H
+
-ATPase subunit (red), and cell nuclei (blue). Pendrin colocalizes in some 
cells with the a4 H
+
-ATPase subunit (arrow, yellow overlay). (D) Staining of patients kidney 
for AE1 (red), AQP2 (white), and pendrin (green). Nuclei are stained in blue. No staining for 
pendrin was detectable in the patient’s kidney but all cells in the collecting duct (*) were 
positive for AQP2. (E,F,G) Patient’s kidney stained for the B1 H+-ATPase subunit (red, E), 
and AQP2 (white, F), panel G depicts the overlay of all channels. All cells are positive for 
AQP2 but some cells have also a weak but distinct luminal red staining suggesting 
colocalization of AQP2 and B1 in the same cells. Original magnification 400-630 x. 
 
Figure 2: Autoantibodies against renal intercalated cells and gastric parietal cells 
(A) Incubation of healthy human kidney with serum from a control person (red, 1:1000) and 
staining of type A intercalated cells with antibodies against AE1 (green). No specific red 
staining detectable. (B) Incubation of healthy human kidney with patient’s serum (red, 
1:1000) and antibodies against AE1 (green) demonstrating specific staining of type A 
intercalated cells. (C) Incubation of healthy human kidney with patient’s serum (red) and 
antibodies against AE1 (green) and AQP2 (white) demonstrates staining with autoantibodies 
of cells negative for AQP2 and positive (asterisk: type A intercalated cells) or negative for 
AE1(arrow: type B intercalated cells). (D) Incubation of healthy human stomach with 
patient’s serum (red) and antibodies against gastric -H+/K+-ATPase (green), a marker of 
acid-secretory parietal cells, showing partial colocalization of both signals indicated by the 
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yellow color. Insert with higher magnification of parietal cells (1000x magnification). 
Original magnification 400 x. 
12 
 
References 
1. Unwin RJ, Shirley DG, Capasso G. Urinary acidification and distal renal tubular 
acidosis. J Nephrol. 2002;15 Suppl 5:S142-50. 
2. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 
2002;13(8):2160-70. 
3. Cohen EP, Bastani B, Cohen MR, Kolner S, Hemken P, Gluck SL. Absence of H(+)-
ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal 
tubular acidosis. J Am Soc Nephrol. 1992;3(2):264-71. 
4. Walsh S, Turner CM, Toye A, Wagner C, Jaeger P, Laing C, et al. 
Immunohistochemical comparison of a case of inherited distal renal tubular acidosis (with a 
unique AE1 mutation) with an acquired case secondary to autoimmune disease. Nephrol Dial 
Transplant. 2007;22(3):807-12. 
5. Han JS, Kim GH, Kim J, Jeon US, Joo KW, Na KY, et al. Secretory-defect distal renal 
tubular acidosis is associated with transporter defect in H(+)-ATPase and anion exchanger-1. 
J Am Soc Nephrol. 2002;13(6):1425-32. 
6. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification assessed by 
simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. 
Kidney Int. 2007;71(12):1310-6. 
7. Blomqvist SR, Vidarsson H, Fitzgerald S, Johansson BR, Ollerstam A, Brown R, et al. 
Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. J Clin 
Invest. 2004;113(11):1560-70. 
8. Batlle D, Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis. 
Nephrol Dial Transplant. 2012;27(10):3691-704. 
9. Kandasamy N, Fugazzola L, Evans M, Chatterjee K, Karet F. Life-threatening 
metabolic alkalosis in Pendred syndrome. Eur J Endocrinol. 2011;165(1):167-70. 
13 
 
10. Wagner CA, Mohebbi N, Capasso G, Geibel JP. The anion exchanger pendrin 
(SLC26A4) and renal acid-base homeostasis. Cell Physiol Biochem. 2011;28(3):497-504. 
11. Pela I, Bigozzi M, Bianchi B. Profound hypokalemia and hypochloremic metabolic 
alkalosis during thiazide therapy in a child with Pendred syndrome. Clin Nephrol. 
2008;69(6):450-3. 
12. Xu J, Song P, Nakamura S, Miller M, Barone S, Alper SL, et al. Deletion of the 
chloride transporter slc26a7 causes distal renal tubular acidosis and impairs gastric acid 
secretion. J Biol Chem. 2009;284(43):29470-9. 
13. Gaarder PI, Heier HE. A human autoantibody to renal collecting duct cells associated 
with thyroid and gastric autoimmunity and possibly renal tubular acidosis. Clin Exp Immunol. 
1983;51(1):29-37. 
 
 
Figure 1 
* 
* 
C A 
B 
G 
D 
* 
E F 
C 
* 
A 
B 
D 
Figure 2 
